Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek November 1, 2004 Amy Barrett	This Pep Pill is Pushing Its Luck Half of Provigil prescriptions may be for "off-label" uses. Did its maker cross the line? But Cephalon is hardly the only drugmaker in the spotlight.
The Motley Fool March 24, 2006 Brian Gorman	Cephalon Takes a Hit The FDA rules against its ADHD drug, but Cephalon's current lineup still holds promise. Investors may want to look at the current sell-off as a potential buying opportunity.
BusinessWeek April 24, 2006 Arlene Weintraub	A Cephalon Vet Takes On Insomnia Jack Lief helped create Provigil, the elixir of wakefulness. But his startup is committed to helping people sleep.
BusinessWeek July 2, 2007 Arlene Weintraub	Lifestyle Drug Binge The huge profits in weight-loss and other treatments makes them hard for drugmakers to resist. But safety risks abound.
The Motley Fool August 19, 2004 Charly Travers	1 Pill for Sleep, Attention Ailments? Cephalon gets some good news about its drug PROVIGIL.
The Motley Fool September 9, 2010 Brian Orelli	Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September.
Pharmaceutical Executive March 1, 2007 Walter Armstrong	He's Just Being Frank Cephalon's Frank Baldino is going global with plans to corner cancer.
The Motley Fool June 27, 2006 Brian Lawler	Cephalon Stays Busy The announcement of Gabitril's phase 3 failure was definitely not good news for Cephalon. However, if the market panics and drives the stock down, investors could find themselves with a great buying opportunity.
The Motley Fool November 22, 2006 Brian Lawler	How to Market a Drug Too Well Cephalon's promotion of its pain drug Actiq might have crossed the line.
The Motley Fool April 2, 2007 Brian Lawler	FDA Keeps Cephalon Waiting The FDA issues Cephalon an approvable letter for one of its drugs. Investors, take note.
Wired November 2003 Richard Martin	It's Wake-Up Time Kiss your pillow good-bye. A new breed of drugs promises to do for drowsiness what Prozac did for depression.
The Motley Fool April 16, 2008 Brian Lawler	Cephalon Convinces the Continent The pharmaceutical's lead pain drug gets approved for marketing in Europe.
Pharmaceutical Executive April 1, 2011	Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool February 17, 2006 Brian Gorman	Enthusiasm for Cephalon The company seems to be counting on a strong showing for a new drug, but for investors, it may pay to be cautious.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool July 6, 2006 Brian Lawler	Cephalon on the Hunt The biopharma company is looking to make more acquisitions and gets some good news from the FDA. Cephalon's stock climbed by more than 10% after the announcement.
The Motley Fool June 27, 2005 Brian Gorman	Alkermes' Powerful Partnership Alkermes recently agreed to partner with Cephalon to commercialize Alkermes' Vivitrex, an experimental drug to treat alcoholism. The deal should bring strong sales and valuable experience.
The Motley Fool March 30, 2010 Brian Orelli	FDA Lags, Investors Flee Cephalon gets no love from the FDA. The agency failed to expand Cephalon's Nuvigil for the treatment of jet lag.
ifeminists May 24, 2006 Gerald K. McOscar	ADHD Is it child abuse per se for parents to allow doctors to prescribe mind altering drugs with potentially serious or fatal psychiatric side effects to their children, no matter how challenged...or challenging?
The Motley Fool September 26, 2006 Brian Lawler	A Savior for Cephalon? The FDA's approval of Fentora comes just in time for the drug company. Investors, take note.
The Motley Fool May 7, 2008 Brian Lawler	Cephalon's Long Shot Falls Short An FDA advisory panel brings bad news for the company.
The Motley Fool December 31, 2007 Brian Lawler	Cephalon's Date With the FDA In the last day of the year, Cephalon announces that it has submitted another New Drug Application for oncology treatment Treanda. Expect to hear back from FDA on this priority review before the middle of 2008.
The Motley Fool May 31, 2011 Brian Orelli	Pay Attention, Biotech Investors Competitors and partners can't be ignored.
The Motley Fool June 29, 2010 Brian Orelli	The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool February 14, 2008 Brian Lawler	Waking Cephalon Up Specialty pharma Cephalon presents its 2007 financial results and 2008 guidance.
BusinessWeek January 26, 2004 Arlene Weintraub	"I Can't Sleep" Insomnia and other sleep disorders are wreaking havoc on our health and taxing the economy. Drug companies see an opportunity.
The Motley Fool November 4, 2004 Charly Travers	Drug Growth Screeching to a Halt Given the threat of generics to not-so-small drug company Cephalon's product line, the acquisition of CIMA labs in August of this year could turn out to be quite important.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool September 14, 2007 Brian Lawler	"Dear Doctor" Letter Spells Trouble for Cephalon Cephalon sends a letter to health-care practitioners warning of the dangers of misusing one of its lead drugs, Fentora. Investors, take note.
The Motley Fool November 6, 2006 Brian Lawler	No Worries About Cephalon This solid biopharma ups its yearly guidance -- for the fourth time. Investors, take note.
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.
Pharmaceutical Executive April 1, 2006 Jill Wechsler	Washington Report: A Warning Trend Washington's new answer to drug safety concerns is more warnings and more disclosure of undigested data. But warnings can go too far. Haven't FDA's critics ever heard the story of the boy who cried wolf?
The Motley Fool February 16, 2007 Brian Lawler	Cephalon's Supercharged Growth The pharmaceutical announces fourth-quarter results and updates 2007 guidance. Investors, take note.
Chemistry World May 4, 2011 Andrew Turley	Teva sidelines Valeant with $6.8bn Cephalon bid US drugmaker Cephalon has agreed to a $6.8 billion ( 4.1 billion) takeover bid from Israeli generics manufacturer Teva, which has beaten into second place Canadian pharma company Valeant.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.
The Motley Fool September 27, 2007 Brian Lawler	FDA Repeats Itself With Cephalon's Fentora In the wake of a letter from Cephalon to health-care practitioners, the FDA has issued a press release and a public health advisory of the dangers of misusing the company's pain drug Fentora. Investors, take note.
Pharmaceutical Executive March 1, 2007 Patrick Clinton	From the Editor: Incurable Eventually we're going to have lifestyle drugs, powerful ones that will make amazing differences in how we live.
BusinessWeek December 11, 2006 Michael Arndt	Kills Pain, Cures Rabies, And Grows Hair The prescription drug market is one part Big Brother and one part Wild West.
The Motley Fool August 3, 2007 Brian Lawler	Cephalon's Case of Spending Blues Cephalon announces its second-quarter financial results. Sales were up, so why is the share price down? Perhaps escalating SG&A expenses are the culprit.
The Motley Fool January 31, 2011 Brian Orelli	Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet.
The Motley Fool April 11, 2011 Jim Mueller	A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too.
The Motley Fool November 9, 2007 Brian Lawler	Cephalon Wheels and Deals Sales and net income fall in the third quarter, but increased guidance sends shares of the drugmaker higher.
The Motley Fool August 27, 2007 Brian Lawler	Cephalon Makes A Deal The newest drug in its cabinet is expected to hit the U.S. market in the fourth quarter. Investors will know relatively soon whether Cephalon pulled off another coup or just flushed $100 million down the toilet.
BusinessWeek June 24, 2010 Bliss & Decker	Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete.
The Motley Fool April 1, 2008 Brian Lawler	Cephalon Plays "Let's Make a Deal" Cephalon acquires an oncology drug on the cheap from tiny Acusphere.
The Motley Fool April 27, 2007 Brian Lawler	Cephalon's Earnings Surprise The drugmaker raises its earnings guidance for the year. With no serious competition for its lead compounds in the near term, investors should take a look at the well-run pharma.
The Motley Fool May 14, 2008 Brian Lawler	Teaching Old Drugs New Tricks Pfizer's top drugs post mixed results in recent off-label studies.